Gefapixant
Cough
Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Small moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Cough cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Thalidomide Johns Hopkins University | Phase 3 | BB |
Alpha-Interferon Ainos, Inc. (f/k/a Amarillo Biosciences Inc. | Phase 2 | CCC |
SUPLATAST TOSYLATE Melius Pharma AB | Phase 2 | CCC |
Capsaicin University of Florida | Phase 1/2 | CCC |
Orvepitant Nerre Therapeutics Ltd. | Phase 2 | CC |
Azithromycin Insel Gruppe AG, University Hospital Bern | N/A | D |
Same molecule, other indications
Gefapixant is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →